Is Moderna (MRNA) Stock a Scam?

Is Moderna (MRNA) stock a scam?  Serious question!  While they have been releasing positive Covid-19 vaccine data over the past few months, company insiders have been dumping stock as fast as they can.  Here is a look at the insider sales below:

July 2020 - Over 40 insider sales amounting to over 200,000 shares sold
June 2020 - Over 40 insider sales amounting to over 200,000 shares sold
Largest Insider Block Sale - Lori Henderson sold 64,000 shares at $63.03 for 4.03 million on June 18, 2020.

This is only two months!  Moderna (MRNA) insiders have been selling large amounts of stock all year.  At the very least, it is a major red flag and the SEC should investigate!

We will keep an eye on this situation and report an update in 2021.

Follow me @stockstobuy on Twitter

Stocks to Buy 2021

Marina Biotech, Inc. (MRNA) Wins New Patent

By Tim - http://stockstobuy.org

Marina Biotech, Inc. (MRNA), a biotechnology company that focuses on the discovery, development, and commercialization of oligonucleotide therapies based on RNA interference (RNAi) and RNA (mRNA) transcriptions, won a new patent this morning.

Marina Biotech, Inc. (MRNA) stock is currently trading at $0.24, Up 14%

Marina Biotech Receives Notice of Allowance for U.S. Patent Related to Its Nucleic Acid-Peptide Drug Delivery Platform

Expands Patent Protection to an Extensive Library of Novel Cell-Targeting and Cell-Penetrating Peptides

Marina Biotech, Inc. (NASDAQ:MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/955,207 with claims that cover a library of over 1x10(15) novel peptides. The patent application is part of the Company's proprietary Trp Cage Library patent portfolio. This allowance strengthens the Company's nucleic acid-peptide drug delivery platform, and further expands the Company's patent protection for its comprehensive set of nucleic acid delivery technologies, which also include DiLA2™, SMARTICLES® and the tkRNAi™ system.

"A primary advantage of this patented peptide library is the ability to rapidly screen and identify novel peptides that exhibit cell specific targeting characteristics for directed delivery of nucleic acid therapeutics," said Barry Polisky, Ph.D., Chief Scientific Officer of Marina Biotech. "Delivery remains a significant challenge in the nucleic acid therapeutic space, and peptides with high affinity and specificity are expected to be a fundamental component to developing delivery approaches to a wide spectrum of tissues and cell types. In addition, the library may also be exploited to screen for peptides that function as specific antagonists, agonists or generally exhibit drug like properties."

http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-newsArticle&ID=1602433&highlight=

Today's Biggest Stock Gainers - Top 2011 Stock Gainers - Top 2011 Penny Stock Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Stocks for 2011

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/

MDRNA MRNA Stock News FDA Approval

MDRNA, Inc. (MRNA) is out today ( June 9, 2009 ) with FDA approval news below. MRNA stock is up 150% now to $3.90. Discuss MRNA

Discuss Stocks - http://stockstobuy.org

MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis

Par Pharmaceutical Companies, Inc. Launches Product

Jun 9, 2009 -- MDRNA, Inc. (NasdaqGM:MRNA) announced today that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE:PAR) has launched the product.

Calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin® nasal spray, marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin® were approximately $112 million in 2008, according to IMS Health data.

On March 31, 2009, MDRNA and Par entered into an agreement under which Par acquired the Company's Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray and the Company's FDA-approved, cGMP manufacturing facility in Hauppauge, New York, for an upfront cash payment and profit sharing on commercial sales for five years.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Hot Penny Stocks 2/13/09 February 13, 2009

Today, 2/13/09, there are a few penny stock gainers breaking out to the upside. Be sure to check out the Top 2009 Penny Stock Gainers on the NYSE, Nasdaq, and AMEX.

Penny Stock Gainers - February 13, 2009

Sirius Satellite Radio ( SIRI ) - $0.09 Up 26% - Sirius XM still in talks with Liberty: source

MDRNA ( MRNA ) - $0.39 Up 56.06% - MDRNA, Inc. Announces Licensing Agreement With Roche.

Canadian Superior Energy ( SNG ) - $0.59% Up 17.97% - Canadian Superior Updates Shareholders.

Check out the biggest stock gainers today.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free.

Hot Penny Stocks 1/13/09 - January 13, 2009

Today, 1/13/09, there are several penny stock gainers breaking out to the upside. Be sure to check out the Top 2009 Penny Stock Gainers on the NYSE, Nasdaq, and AMEX.

Keryx Biopharmaceuticals ( KERX ) - $0.29 Up 26.43% - Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference

Zhone Technologies ( ZHNE ) - $0.19 Up 23% - Zhones MSAP Selected for Pioneering Sale of Branded DSL and Voice Services through Fast-Growth Retail Chain La Curacao.

MDRNA ( MRNA ) - $0.44 Up 15% - MRNA is going up on no news today....double average volume already by 10:50am est.

Check out the biggest stock gainers today.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free